
Column elution firstly by 10mM (open arrow), followed by 100mM (filled arrow), methyl α-D-mannopyranoside.
%
50
40
30
20
10
0

FIG. 1


0.6000
F5
ST
F4
[Abs]
260
280
0.0000
250.0
Wavelength (nm)
300.0

FIG. 2


Elution by 10mM methyl α-D-mannopyranoside
50
40
30
20

FIG. 3


0.13500
[Abs]
-0.0150
97.4
A=0.1073
260
280
TUB Nº 7
INSOL. 37ºC
250.0
Wavelength (nm)
300.0

FIG. 4


Elution by 10mM methyl α-D-mannopyranoside
100
90
80
70
60
%
50
40
30
20
10
0

FIG. 5



FIG. 6



FIG. 7


Kratos Kompact MALDI 3 V4.0.0: + Linear High Power: 90
%Int. 100% = 14 mV [sum= 749 mV] Shots 1-50 Smooth Av 100
26412
100
90
80
70
60
50
40
30
20
10
0
10000
15000
20000
25000
30000
35000
40000
45000
50000
Mass/Charge

FIG. 8


Columns A & B:
elution firstly by 10mM (open arrows), followed by 100mM (filled arrows), methyl α-D-mannopyranoside.
A
B
%
%
18050-98

FIG. 9


A.
0.4000
[Abs]
0.0000
A. Without Glucose
260
280
250.0
Wavelength (nm)
300.0


B.
0.1380
[Abs]
0.0000
B. With Glucose
260
280
250.0
Wavelength (nm)
300.0

FIG. 10



FIG. 11



FIG. 12

SCHEME OF PREFERRED EMBODIMENTS OF METHOD FOR EXAMPLE OF RECOMBINANT FORMS OF CONCANAVALIN A



FIG. 13